Form 4: Nautilus Biotechnology Director Granted 45,000 Stock Options

Matthew S. McIlwain, a Director at Nautilus Biotechnology, Inc., was granted 45,000 stock options with an exercise price of $0.6951, vesting monthly over one year.

Summary

• Matthew S. McIlwain, a Director of Nautilus Biotechnology, Inc. (NAUT), was granted 45,000 stock options.
• The options have an exercise price of $0.6951 per share.
• The grant date for these options was June 23, 2025.
• The options are exercisable until June 23, 2035.
• Vesting occurs monthly, with one-twelfth (1/12th) of the shares vesting each month following the grant date, contingent on Mr. McIlwain's continuous status as a "Service Provider" under the Issuer's 2021 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation event for a director, which is generally viewed positively as it aligns interests and incentivizes performance, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the stock options is dependent on the future performance of Nautilus Biotechnology's stock price; if the stock price does not exceed the exercise price of $0.6951, the options may expire worthless.
• The vesting of options is contingent on the director's continuous service, meaning unvested options would be forfeited if service terminates prematurely.

Future Outlook

The stock options granted to Director Matthew S. McIlwain will vest monthly over a one-year period following the grant date of June 23, 2025, contingent on his continuous service as a "Service Provider" to the company. The options have an expiration date of June 23, 2035.

Industry Context

Granting stock options to directors and executives is a standard practice in the biotechnology and technology sectors. It serves as a common form of equity compensation designed to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term performance of the company's stock. This particular grant to a director is consistent with typical corporate governance and compensation strategies aimed at fostering shareholder value.

Comparison to Industry Standards

• The practice of granting stock options to directors is a common compensation mechanism across the biotechnology and broader technology industries, similar to companies like Illumina, Pacific Biosciences, or other life science tools providers, where equity incentives are crucial for attracting and retaining talent.
• The specific exercise price of $0.6951 is tied to the market price of Nautilus Biotechnology's stock on the grant date, which is standard for at-the-money option grants.
• A monthly vesting schedule over one year is a common approach for director equity grants, providing ongoing incentive for continued service, comparable to vesting schedules seen at many publicly traded companies for similar roles.

Related Party Transactions

• The grant of 45,000 stock options to Matthew S. McIlwain, a Director of Nautilus Biotechnology, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders by incentivizing stock price appreciation. However, it also represents potential future dilution if the options are exercised.
• Employees: While not directly impacting employees, the use of equity incentives for directors reflects a broader compensation strategy that may also extend to key employees.
• Management: The grant reinforces the compensation structure for key personnel, potentially aiding in retention and motivation.

Next Steps

• The granted stock options will begin vesting monthly from June 23, 2025, over a one-year period.
• The director, Matthew S. McIlwain, will continue to serve on the board, subject to the terms of his "Service Provider" status.

Key Dates

Recommendation

Keywords

Nautilus Biotechnology, NAUT, Stock Option, Form 4, SEC Filing, Director Compensation, Equity Incentive Plan, Matthew S. McIlwain, Insider Transaction